ADVERTISEMENT

Emily Bader

News

FDA Approves Axicabtagene Ciloleucel for Relapsed or Refractory LBCL

04/04/2022

The FDA approved axicabtagene ciloleucel for patients with LBCL that are refractory to or have relapsed within 12 months of first-line chemoimmunotherapy.

The FDA approved axicabtagene ciloleucel for patients with LBCL that are refractory to or have relapsed within 12 months of first-line chemoimmunotherapy.

The FDA approved axicabtagene...

04/04/2022

Oncology

Conference Insider

Dr Martin Discusses How to Approach MCL

03/23/2022

Peter Martin, MD, discusses how to approach MCL, including what’s been learned so far and what’s to be expected, at the virtual Great Debates & Updates in Hematologic Malignancies.

Peter Martin, MD, discusses how to approach MCL, including what’s been learned so far and what’s to be expected, at the virtual Great Debates & Updates in Hematologic Malignancies.

Peter Martin, MD, discusses how...

03/23/2022

Oncology

Featured Webinar

Implementing ERAS Protocols Throughout Patient Peri-Op Journey: Reductions in Complications

Advertisement

Advertisement

Advertisement

Upcoming Events

December 4 ⁠–⁠ December 5

Great Debates & Updates in Diabetic Foot

December 6 ⁠–⁠ December 7

December 9 ⁠–⁠ December 11

December 9 ⁠–⁠ December 11

December 12 ⁠–⁠ December 13

December 14 ⁠–⁠ December 15

February 2 ⁠–⁠ February 5

February 27 ⁠–⁠ March 1

DCLF

March 17 ⁠–⁠ March 19

NP Institute

March 27 ⁠–⁠ March 30

See Full Calendar

Advertisement

Advertisement